Research looks for new antibiotics
M. abscessus can cause devastating lung infections in people with cystic fibrosis, and instances of infection are growing each year. The Cystic Fibrosis Trust has launched a new Strategic Research Centre (SRC), led by Professor Floto at the University of Cambridge, to find new treatments and strategies to overcome the many challenges M. abscessus can bring.
Paula Sommer, Head of Research at the Cystic Fibrosis Trust, said: “It’s really exciting to be launching a new SRC to find a treatment for this M. abscessus. It’s a bacteria that could affect anyone with CF, and has such an impact – infection with it means you are no longer eligible for lung transplant, despite the acceleration in lung damage it causes.
“This research will take place over four years and we hope it will lead to treatments that will transform the lives of everyone affected by this bacteria across the globe.”
Researchers from the University of Cambridge, the Wellcome Trust Sanger Institute and Colorado State University will use their combined expertise and some exciting technologies to work out how best to treat and prevent infection with the bacteria. This builds on the work of a previously announced SRC investigating the pathophysiology of M. abscessus (the way in which it causes harm in the human body).
Professor Floto, the Principal Investigator, said: “We’re delighted to have received funding to pursue this crucial challenge. We’re working with world-class experts and some fascinating new technologies, and hopefully we’ll come out the other side of this project with effective tools for fighting one of the most devastating infections that affects people with cystic fibrosis.”